title: [Persistence of hypercoagulability state after hip and knee arthroplasty: what is the optimal duration of antithrombotic guidelines in this surgery?].
abstract: Among 79 patients candidates to hip (53) and knee (26) replacement an evaluation was made of the influence of a two-week program with LMWH on the evolution of hypercoagulability markers: D-D, TAT, and F1 + 2. Measurements were performed by ELISA preoperatively and on days 1, 7 and about 45 postoperatively; in the latter, two extraction intervals were considered: < or = 45 days and > 45 days. With both surgical modalities, D-D and F1 + 2 peaked at 7th day postoperatively, whereas TAT peaked on day 1. Among D-D and F1 + 2 values quantitated on day 7th and the extraction interval < or = 45 days, no significant differences were obtained (Z < 2.64). The hypercoagulative chronicity exhibited by D-D and F1 + 2 during the first month and a half after this surgery, might require in some cases a more prolonged thromboprophylaxis.
authors.affiliation: Servicio de Hematología, Hospital Clínico Universitario de Zaragoza.
authors.forename: T
authors.initials: T
authors.lastname: Iturbe Hernández
authors.forename: R
authors.initials: R
authors.lastname: Cornudella Lacasa
authors.forename: R
authors.initials: R
authors.lastname: de Miguel Olmeda
authors.forename: G
authors.initials: G
authors.lastname: Azaceta Reinares
authors.forename: M A
authors.initials: MA
authors.lastname: Fuertes Palacio
authors.forename: F
authors.initials: F
authors.lastname: Seral Iñigo
authors.forename: M
authors.initials: M
authors.lastname: Gutiérrez Martín
mesh_terms: D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D015415:Biomarkers; D001779:Blood Coagulation Factors / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D019851:Thrombophilia / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D013997:Time Factors
chemical_list: D015415:Biomarkers; D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases